血栓凝结学和凝血指标在预测癌症患者血栓栓塞风险方面的联合作用
Liqiu Huang1, Wei Dong2, Xiaojie Hu3
1Department of Laboratory, Tangshan Central Hospital, Tangshan, Hebei, China.
Frontiers in medicine
|September 11, 2025
概括
血栓形成显微镜 (TEG) 和关键凝血指标有效评估癌症患者的血栓栓塞 (TE) 风险. 检测这些标志物有助于识别高风险个体,以便主动管理.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 癌症患者患血栓栓塞 (TE) 的风险更高.
- 准确的风险评估对于及时干预至关重要.
- 血小板结晶学 (TEG) 和凝血参数是潜在的生物标志物.
研究的目的:
- 评估TEG和四个凝血指标在评估癌症患者TE风险中的应用价值.
- 在这个人群中确定用于预测TE的关键指标.
主要方法:
- 对160名癌症患者的临床数据进行了回顾性分析.
- 分类为TE组 (45名患者) 和非TE组 (115名患者).
- 对TEG参数 (角度,MA,K,R) 和凝血指标 (D-二聚体,纤维素,APTT,PT,PLT) 的分析.
主要成果:
- 在TE组中,TEG参数Angle和MA显著较高,而K和R则较低 (P<0.05).
- 在TE组中,D-二聚和纤维素水平较高,而APTT,PT和PLT在TE组中较低 (P<0.05).
- 二元逻辑回归确定了Angle,MA,K,R,D-dimer,APTT,PT和PLT作为TE的显著影响因素 (P<0.05).
结论:
- TEG和凝血指数检测在癌症患者TE风险评估中具有显著价值.
- 这些标志物可以帮助识别患有高血栓栓塞事件风险的癌症患者.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Venous Thrombosis IV: Nursing Management
202
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
202
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
294
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
294
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
329
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
329
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


